Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

  title={Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.},
  author={Ian C Smith and Steven D. Heys and Andrew W. Hutcheon and Iain D. Miller and Simon Payne and Fiona J. Gilbert and Antoinne K Ah-See and O. G. Eremin and Leslie G. Walker and Tarun Kumar Sarkar and S Peter Eggleton and Keith N. Ogston},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={20 6},
PURPOSE To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT). PATIENTS AND METHODS Patients with large or locally advanced breast cancer received four pulses of cyclophosphamide 1,000 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.5 mg/m(2), and prednisolone 40 mg (4 x CVAP) for 5 days. Clinical tumor response was… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS


Publications citing this paper.
Showing 1-10 of 289 extracted citations

Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2004
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…